RMCM
IONS icon

Reynders McVeigh Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Reynders McVeigh Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,174
Closed -$547K – 239
2021
Q1 		$547K Sell
12,174
-4,721
-28% -$263K 0.04% 147
2020
Q4 		$955K Buy
16,895
+785
+5% +$39.1K 0.07% 105
2020
Q3 		$764K Sell
16,110
-530
-3% -$29.4K 0.06% 117
2020
Q2 		$981K Sell
16,640
-1,750
-10% -$97.4K 0.09% 103
2020
Q1 		$869K Sell
18,390
-2,200
-11% -$123K 0.1% 97
2019
Q4 		$1.24M Hold
20,590
– – 0.12% 93
2019
Q3 		$1.23M Sell
20,590
-1,520
-7% -$99.1K 0.13% 92
2019
Q2 		$1.42M Buy
22,110
+150
+0.7% +$10.6K 0.15% 84
2019
Q1 		$1.78M Buy
21,960
+3,400
+18% +$219K 0.2% 73
2018
Q4 		$1M Buy
18,560
+10,500
+130% +$536K 0.13% 94
2018
Q3 		$416K Sell
8,060
-5,035
-38% -$237K 0.05% 147
2018
Q2 		$546K Sell
13,095
-625
-5% -$27.7K 0.07% 129
2018
Q1 		$605K Sell
13,720
-225
-2% -$11.4K 0.08% 125
2017
Q4 		$701K Sell
13,945
-425
-3% -$23.3K 0.09% 113
2017
Q3 		$729K Sell
14,370
-1,625
-10% -$85.1K 0.1% 110
2017
Q2 		$814K Sell
15,995
-1,150
-7% -$53.6K 0.11% 108
2017
Q1 		$689K Sell
17,145
-4,275
-20% -$192K 0.09% 120
2016
Q4 		$1.02M Sell
21,420
-10,740
-33% -$425K 0.15% 99
2016
Q3 		$1.18M Sell
32,160
-25,823
-45% -$808K 0.17% 89
2016
Q2 		$1.35M Sell
57,983
-54,814
-49% -$1.77M 0.2% 84
2016
Q1 		$4.57M Buy
112,797
+275
+0.2% +$11.2K 0.68% 37
2015
Q4 		$6.97M Buy
112,522
+1,209
+1% +$65.2K 1.14% 26
2015
Q3 		$4.5M Buy
111,313
+925
+0.8% +$47.9K 0.78% 33
2015
Q2 		$6.35M Sell
110,388
-1,330
-1% -$84.6K 1.04% 28
2015
Q1 		$7.11M Buy
111,718
+1,235
+1% +$83.8K 1.22% 27
2014
Q4 		$6.82M Buy
110,483
+2,625
+2% +$130K 1.2% 29
2014
Q3 		$4.19M Buy
107,858
+37,575
+53% +$1.33M 0.8% 35
2014
Q2 		$2.42M Buy
70,283
+49,203
+233% +$1.55M 0.55% 42
2014
Q1 		$911K Buy
21,080
+12,915
+158% +$626K 0.22% 79
2013
Q4 		$325K Buy
+8,165
New +$291K 0.08% 132

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Reynders McVeigh Capital Management's IONS Position: Q2 2021 in Review

Reynders McVeigh Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2021, closing a stake of 12,174 shares — an estimated $547K sold.

Reynders McVeigh Capital Management first reported a position in IONS in Q4 2013 and held it in 30 quarters. The position peaked at $7.11M in Q1 2015. 337 funds tracked by Wall St. Rank hold IONS as of Q2 2021.

  • Reynders McVeigh Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Reynders McVeigh Capital Management sold 12,174 Ionis Pharmaceuticals shares in Q2 2021, an estimated $547K.
  • Reynders McVeigh Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2013 and held it in 30 quarters.
  • Reynders McVeigh Capital Management's Ionis Pharmaceuticals position peaked at $7.11M in Q1 2015.
  • 337 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2021.

Based on Reynders McVeigh Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.